Mitochondrially targeted anti-cancer agents

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F10%3A00361635" target="_blank" >RIV/86652036:_____/10:00361635 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.mito.2010.06.004" target="_blank" >http://dx.doi.org/10.1016/j.mito.2010.06.004</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.mito.2010.06.004" target="_blank" >10.1016/j.mito.2010.06.004</a>

Result language
angličtina
Original language name
Mitochondrially targeted anti-cancer agents
Original language description
Cancer is an ever-increasing problem that is yet to be harnessed. Frequent mutations make this pathology very variable and, consequently,a considerable challenge.Mitochondria have recently emerged as novel targets for cancer therapy. A group of agents with anti-cancer activity that induce apoptosis by way of mitochondrial destabilisation, termed mitocans,have been a recent focus of research.Of these compounds, many are hydrophobic agents that associate with various subcellular organelles.Modification ofsuch structures with mitochondria-targeting moieties,for example tagging them with lipophilic cations,would be expected to enhance their activity. This may be accomplished by the addition of triphenylphosphonium groups that direct such compounds to mitochondria, enhancing their activity. We propose that mitochondrial targeting, in particular where the agent associates directly with the target,results in more specific and efficient anti-cancer drugs of potential high clinical relevance
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)